乙型流感病毒核酸PCR檢測試劑盒

廣州健侖生物科技有限公司

產(chǎn)品規(guī)格：48T/盒；

 保存條件：避光 -20度 保存。

    我司還提供各種流感病毒、副流感病毒、呼吸道合胞病毒、冠狀病毒、輪狀病毒、桿菌、鏈球菌、熱帶病毒等等核酸檢測試劑盒（PCR-熒光探針法），還有各種原料和質(zhì)控品，隨時歡迎您的來電：  楊

以下是我司提供的部分PCR產(chǎn)品

乙型流感病毒核酸PCR檢測試劑盒

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

以下是部分呼吸道類致病細菌PCR檢測試劑盒

乙型流感病毒核酸PCR檢測試劑盒

想了解更多的產(chǎn)品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

根據(jù)病毒的核蛋白，流感可分為A、B、C、D 4個主要抗原型，或叫甲、乙、丙、丁型；其中A型和B型較常見，C型和D型不多見。B型主要有兩種亞型： Victoria型和Yamagata型。從去年底到今年初增加的流感病例中，B型占了很大比例，其中Yamagata型明顯增多。

解讀：乙型流感病毒有所變異

季節(jié)性流感幾乎每年都有，有時甚至一年不止暴發(fā)一次。雖然，它跟多數(shù)普通感冒一樣都是由病毒感染引起的，但病毒經(jīng)常有變異，有時會讓人措手不及。

“流感至今仍是我們無法預測的威脅。”鐘南山解釋說，不像天花的毒株是固定的，流感的毒株老是在變，能不斷逃避人群對它的免疫攻擊。他引用國家流感中心數(shù)據(jù)指出，2017年4月以來，我國流行的A型（H3N2）,甲型H1N1，B型流感病毒均未發(fā)生明顯變異，流行毒株與北半球推薦的2017~2018年疫苗株匹配性較好。目前我國使用的疫苗為三價流感疫苗，包含A（H1N1）pdm09,A（H3N2）和B型的（Victoria）這3種抗原組分。但從去年底到今年初，乙型流感病毒又有所變異，B型的Yamagata型明顯增多，現(xiàn)有乙型疫苗的匹配性跟不上，未能對目前這波流感起到預防作用，人群對這一新病毒亞型缺乏免疫力，所以發(fā)病數(shù)翻倍。

According to the influenza virus nucleoprotein, can be divided into A, B, C, D 4 major anti prototype, or a, B, C, D; A and B are common, C type and D type rare. There are two main subtypes of B type: Victoria type and Yamagata type. Of the increased number of influenza cases from the end of last year to the beginning of this year, the B type accounted for a large proportion, of which the Yamagata type was significantly increased.

Interpretation: influenza B virus variation

Seasonal flu has almost every year, and sometimes even more than once a year. Although it is caused by most common cold, it is caused by virus infection, but the virus often has variation, sometimes it can make people unprepared.

"The flu is still a threat that we can't predict." Zhong explained that, unlike smallpox virus is fixed, flu strains are always changing, we can escape the attack on its immune population. He cited the data from the National Influenza Center, pointing out that since April 2017, there has been no significant variation in the prevalence of A (H3N2), type a H1N1 and B influenza viruses in China. The epidemic strains are well matched with the recommended 2017~2018 vaccine strains in the northern hemisphere. At present, the vaccine used in China is a trivalent influenza vaccine, which contains 3 kinds of antigen components, A (H1N1) pdm09, A (H3N2) and B type (Victoria). But from the end of last year to early this year, and the variation of influenza virus type Yamagata, type B increased significantly, the existing hepatitis vaccine, can not keep up, the current wave of flu failed to play a preventive role, people lack of immunity to this new virus subtype, so the incidence doubled.